Clinical trials: Pioglitazone
Type 2 Diabetes
INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes
T2DM has become an American Epidemic. Currently 8% of the US population has diabetes and rates may be as high as 33% by the year 2050 (1).
- Trial name
- INSPIRE (NCT01087567)
- Testing
- Intensive insulin, Routine Care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio University
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Severe, Refractory Asthma, Airway Inflammation
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Background: Individuals who have severe asthma that is not easily controlled by current treatments are in need of new treatments to prevent potentially life-threatening asthma attacks.
- Conditions
- Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction
- Trial name
- NCT00994175
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
HIV Infections, Hepatic Steatosis
Pioglitazone to Treat Fatty Liver in People With HIV Infection
This study will determine whether pioglitazone (Actos, a drug approved to treat diabetes, can benefit HIV-infected people with fatty liver.
- Conditions
- HIV Infections, Hepatic Steatosis, Insulin Resistance
- Trial name
- NCT00441272
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 2 Diabetes
Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines
The obesity and type 2 diabetes mellitus (T2DM) are among the most threatening health crisis for the 21st century. Currently, it is estimated that there are 205 million people with T2DM worldwide.
- Trial name
- PRODIGIES (NCT01974544)
- Testing
- Best medical treatment, gastric bypass, sleeve gastrectomy
- Where
- Chile
- Volunteers
- 150 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
- Trial name
- NCT00411892
- Testing
- pioglitazone, inhaled human insulin
- Where
- 110 sites in United States
- Volunteers
- 196 people
- Sponsor
- Novo Nordisk A/S
Stroke, Myocardial Infarction
Insulin Resistance Intervention After Stroke Trial
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Trial name
- IRIS (NCT00091949)
- Testing
- pioglitazone
- Where
- 183 sites in United States, Australia and 6 more
- Volunteers
- 3,876 people
- Sponsor
- Yale University
Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and…
- Trial name
- NCT02875821
- Testing
- Ipragliflozin, metformin with pioglitazone
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Yonsei University
Diabetes Mellitus
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.
- Trial name
- NCT00770952
- Testing
- Pioglitazone and Glimepiride, Glimepiride
- Where
- 17 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication) and pharmacodynamics (what the medication does to the body) of treatment with JNJ-41443532 relative to…
- Trial name
- NCT01230749
- Testing
- JNJ-41443532, Pioglitazone 30 mg
- Volunteers
- 89 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 26.
- Trial name
- EPIDOTE (NCT03499704)
- Testing
- Pioglitazone + Alogliptin, Alogliptin, Metformin
- Where
- 15 sites in South Korea
- Volunteers
- 133 people
- Sponsor
- Celltrion Pharm, Inc.
Coronary Artery Disease, Angina Pectoris
Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients
Patients with diabetes have worse outcomes after percutaneous coronary intervention (PCI) procedures, compared to those patients without diabetes.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Type 2 Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- PPAR-G (NCT00819325)
- Testing
- pioglitazone, oral hypoglycemic agents
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Queen Elizabeth II Health Sciences Centre
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Insulin Resistance, Type 2 Diabetes Mellitus
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
- Trial name
- NCT00212290
- Testing
- pioglitazone, nateglinide
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cystic Fibrosis
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Inflammation clearly contributes to the progression of the cystic fibrosis (CF) lung disease, and administration of the anti-inflammatory agent high-dose ibuprofen retards the rate of decline of pulmonary function.
- Trial name
- NCT00531882
- Testing
- Pioglitazone, Simvastatin, Ibuprofen
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Diabetes Mellitus Type 2
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
This multi-center, randomized, double-blind, active controlled, parallel-group study in type 2 diabetes patients with moderate renal impairment will evaluate the effect on renal function and the safety and tolerability of…
- Trial name
- NCT01043029
- Testing
- aleglitazar, pioglitazone
- Where
- 80 sites in Australia, Brazil and 11 more
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Non-Insulin-Dependent Diabetes Mellitus
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
This study will use Magnetic Resonance Imaging (MRI) techniques to evaluate changes in fluid volume in the lower legs of diabetic patients who add either pioglitazone or placebo to their current diabetic regimen.
- Trial name
- NCT00269061
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
Type-2 diabetes mellitus is a public health concern. Patients with type 2 diabetes mellitus are at high risk of developing cardiovascular complications.
- Trial name
- NCT01040819
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Healthy
Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg
The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl 45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose administration under fed conditions.
- Trial name
- NCT00649012
- Testing
- Pioglitazone HCl Tablets 45 mg, Actos® Tablets 45 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc